All 9 pts are FT836 + cetuximab except 1. There is no need for LD chemo or RT. If cetuximab combo failed, they would have tried the triple combo, not HER2 Ab. U of M would not start another GBM trial with FT536 if targeting mica/b trunk failed in MSS CRC. Watch what the institution doing, why bother with CNS lesions if peripheral lesions didn't respond
Market Data 
Markets 
AI
